Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a new diagnostic research agent named
89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long
89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an
antibody that works against STEAP1 - found on the surface of prostate cancer cells. Attached
to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a
PET scanner. The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A
can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface
with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new
therapies are being developed to target STEAP1 prostate cancer cells.